DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20213067

Evaluation of serum asprosin levels in women with metabolic syndrome in Duhok City-Kurdistan Region/Iraq

Dhia M. Sulaiman

Abstract


Background: Serum asprosin, a recently discovered hormone as a new adipocytokine, which has been associated with the regulation of both glucose and lipid metabolism, and insulin resistance. Metabolic syndrome considered as a disorder of lipid and glucose metabolism, with impairment in insulin function, which might be associated with serum asprosin, therefore, new researches focused on the role of asprosin in the pathogenesis of metabolic syndrome to clarify such relationship. This study aimed to evaluate serum asprosin levels in women with metabolic syndrome and compared with a woman without metabolic syndrome.

Methods: This study was performed at Obstetrics and Gynecology Hospital, and Mazi medical clinics in Duhok, Kurdistan Region-Iraq, the study was established from June, 2020 to January, 2021. In this cross-sectional study, serum asprosin concertation in 40 women with metabolic syndrome were compared with a 131 women without metabolic syndrome. The demographic data were collected, serum asprosin levels, lipid profile, fasting blood glucose, fasting insulin were biochemically analyzed by using the autoanalyzer machine COBASS series 6000 and ELISA technique.

Results: The mean age of women with metabolic syndrome was (24.36±3.23) and women without metabolic syndrome was (23.18±3.87), serum aspersion in women with metabolic syndrome was (18.34±5.4) ng/ml, while in women without metabolic syndrome was (7.48±5.82) with significant difference (p<0.001). In study population, there was a positive correlation between asprosin and body mass index, waist circumference, triglyceride, total cholesterol, fasting blood glucose, fasting insulin, and HOMA-IR (p<0.0001), while serum asprosin was negatively correlated with high density lipoprotein- cholesterol (p<0.01).

Conclusions: The study confirms that serum asprosin in women with metabolic syndrome was higher than in the control group.  


Keywords


Insulin resistance, Asprosin, Metabolic syndrome, White adipose tissue

Full Text:

PDF

References


Haroun D. Metabolic syndrome among adolescents in Dubai, United Arab Emirates, is attributable to the high prevalence of low HDL levels: a cross-sectional study. BMC Public Health. 2018;18(1):1284.

Deniz R. Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome. J Obstet Gynaecol. 2021;41(2):279-84.

Lee Y, CS, Park JH, Shin JH, Lim YH, Park HC et al. Association between insulin resistance and risk of atrial fibrillation in non-diabetics. Eur J Prev Cardiol. 2020;27(18):1934-41.

Ranasinghe P. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review. BMC Public Healt. 2017;17(1):101.

do Vale Moreira NC et al. Prevalence of Metabolic Syndrome by different definitions, and its association with type 2 diabetes, pre-diabetes, and cardiovascular disease risk in Brazil. Diabetes Metab Syndr. 2020.14(5):1217-24.

Corica D. Asprosin serum levels and glucose homeostasis in children with obesity. Cytokine. 2021. 142:155477.

Jung TW. Asprosin attenuates insulin signaling pathway through PKCdelta-activated ER stress and inflammation in skeletal muscle. J Cell Physiol. 2019;234(11):20888-99.

Hoffmann JG, Xie W, Chopra AR. Energy Regulation Mechanism and Therapeutic Potential of Asprosin. Diabetes. 2020;69(4):559-66.

Romere C. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016;165(3): 566-79.

Maylem ERS. Discovery of a possible role of asprosin in ovarian follicular function. J Mol Endocrinol. 2021;66(1):35-44.

Duerrschmid C. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23(12):1444-53.

Gropp E. Agouti-related peptide-expressing neurons are mandatory for feeding. Nat Neurosci. 2005;8(10):1289-91.

Ugur K, Aydin S. Saliva and Blood Asprosin Hormone Concentration Associated with Obesity. Int J Endocrinol. 2019;2019:2521096.

Park SE, Park CY, Sweeney G. Biomarkers of insulin sensitivity and insulin resistance: Past, present and future. Crit Rev Clin Lab Sci. 2015;52(4):180-90.

Zhang H, Hu W, Zhang G. Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease. Int Urol Nephrol. 2020;52(8):1517-22.

Deng X. Higher Serum Asprosin Level is Associated with Urinary Albumin Excretion and Renal Function in Type 2 Diabetes. Diabetes Metab Syndr Obes. 2020;13:4341-51.

Gozel N, Kilinc F. Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin. Endokrynol Pol. 2021;72(1):37-43.

Mazur-Bialy AI. Asprosin-A Fasting-Induced, Glucogenic, and Orexigenic Adipokine as a New Promising Player. Will It Be a New Factor in the Treatment of Obesity, Diabetes, or Infertility? A Review of the Literature. Nutrients. 2021;13(2).

Wang Y. Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion. Mediators Inflamm. 2018;2018:9471583.

Rojas J. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod Med. 2014;2014:719050.

Ke X. Serum Levels of Asprosin, a Novel Adipokine, Are Significantly Lowered in Patients with Acromegaly. Int J Endocrinol. 2020;2020:8855996.

Kocaman N, Kuloglu T. Expression of asprosin in rat hepatic, renal, heart, gastric, testicular and brain tissues and its changes in a streptozotocin-induced diabetes mellitus model. Tissue Cell. 2020;66:101397.

Li X. Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases. Mediators Inflamm. 2018;2018:7375294.

Silistre E, Hatipogl HU. Increased serum circulating asprosin levels in children with obesity. Pediatr Int. 2020;62(4):467-76.

Leonard AN. Fasted plasma asprosin concentrations are associated with menstrual cycle phase, oral contraceptive use and training status in healthy women. Eur J Appl Physiol. 2021;121(3):793-801.

Luis C. A state of the art review on the novel mediator asprosin in the metabolic syndrome. Porto Biomed J. 2020;5(6):e108.

Alan M. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2019;35(3):220-3.

Yang Z. Effect of high-fat diet and exercise on asprosin and CTRP6 expression in subcutaneous and retroperitoneal adipose tissues in rats during mid-gestation. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40(10):1406-14.

Naiemian S. Serum concentration of asprosin in new-onset type 2 diabetes. Diabetol Metab Syndr. 2020;12:65.

Zhang X. Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus. J Diabetes Investig. 2020;11(2):349-55.

Lee T. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol. 2019;486:96-104.92-100.